Conditions: Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Chronic Myelogenous Leukemia Chronic Lymphocytic Leukemia Myelodysplasia Lymphoma, Non-Hodgkin's Mantle-Cell Lymphoma Hodgkin's Disease Multiple Myeloma Myelofibrosis
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease.

This research is being done because there is no completely safe and effective prevention for graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after a transplant known as nonmyeloablative ("mini" transplant).

Detailed description:

Arms:

Interventions: intervention 1: Cyclophosphamide intervention 2: Fludarabine intervention 3: Cyclosporine intervention 4: Mycophenolate mofetil intervention 5: Basiliximab
Intervention descriptions: intervention 1: 60mg/kg/day for two consecutive days (-7,-6). intervention 2: 25mg/m2/day for 5 consecutive days intervention 3: 3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1. intervention 4: 1000 mg will be administered through day +60 and then discontinued if there is no GVHD. intervention 5: 20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.

Protocol document: